NC
RARE icon

nVerses Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

nVerses Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Buy
+7,636
New +$190K 0.39% 100
2024
Q4 		– Sell
-2,700
Closed -$150K – 685
2024
Q3 		$150K Buy
2,700
+1,900
+238% +$96.8K 0.07% 394
2024
Q2 		$32.9K Buy
+800
New +$34.2K 0.02% 678

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

nVerses Capital's RARE Position: Q2 2026 in Review

nVerses Capital opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 7,636 shares worth $255K. The stake represents 0.39% of the portfolio and ranks #100 among its holdings. This is a return to the name: nVerses Capital previously reported a position in RARE as recently as Q3 2024.

nVerses Capital first reported a position in RARE in Q2 2024 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • nVerses Capital held 7,636 shares of Ultragenyx Pharmaceutical worth $255K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new nVerses Capital position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.39% of nVerses Capital's portfolio in Q2 2026, its #100 holding.
  • nVerses Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.